Tue. 26 Mar 2024, 8:35am ET
Benzinga
Biotech, News, General
The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.